Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iRadimedIRMD +0.79%93 EV-to-FCF is 43.69 as of Aug. 26, 2026, which is 0% above its 10-year median of 43.67. GuruFocus rates IRMD with a GF Score™ of 93/100 and a GF Value™ of $65.94 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 409 Medical Devices & Instruments companies, iRadimed ranks worse than 73.84% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, iRadimed's Enterprise Value is $1,072.43 Mil.
iRadimed's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was $24.55 Mil. Therefore, iRadimed's EV-to-FCF for today is 43.69.
The historical rank and industry rank for iRadimed's EV-to-FCF or its related term are showing as below:
IRMD'
s EV-to-FCF Range Over the Past 10 Years
Min: 9.08 Med: 43.67 Max: 117.99
Current: 43.69
During the past 13 years, the highest EV-to-FCF of iRadimed was 117.99. The lowest was 9.08. And the median was 43.67.
IRMD's EV-to-FCF is ranked worse than 73.84% of 409
companies
in the Medical Devices & Instruments industry
Industry Median: 24.43
vs IRMD: 43.69
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
iRadimed's share price for today is $87.87.
iRadimed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.790.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
iRadimed EV-to-FCF Related Terms
iRadimed EV-to-FCF Historical Data
* Premium members only.
The historical data trend for iRadimed's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, iRadimed's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRadimed EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where iRadimed's EV-to-FCF falls into.
iRadimed's current Enterprise Value is $1,072.43 Mil.
iRadimed's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iRadimed (IRMD) has a EV-to-FCF of 43.69 as of Aug. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on iRadimed and its competitors. This is near median its historical median of 43.67. Over the past decade, iRadimed's EV-to-FCF has ranged from 9.08 to 117.99. According to the industry distribution chart, iRadimed ranks #302 out of 409 companies in the Medical Devices & Instruments industry, placing it in the top 73.8%.
Is iRadimed's EV-to-FCF too high?
iRadimed's current EV-to-FCF of 43.69 is near median its 10-year median of 43.67. Over the past 10 years, this metric has ranged from a low of 9.08 to a high of 117.99. The Medical Devices & Instruments industry median EV-to-FCF is 24.43. iRadimed's value of 43.69 is 78.8% above this industry median. Based on the distribution chart, iRadimed ranks #302 out of 409 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, iRadimed has a GF Score™ of 93/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iRadimed's EV-to-FCF compare to AORT and TNDM?
According to the Medical Devices & Instruments industry distribution chart, iRadimed ranks #302 out of 409 companies for EV-to-FCF. This places iRadimed in the lower half of its industry. The industry median EV-to-FCF is 24.43. iRadimed's value of 43.69 is 78.8% above this benchmark. Historically, iRadimed's own EV-to-FCF has ranged from 9.08 to 117.99 over the past decade. While the company's 10-year median is 43.67 vs. the industry median of 24.43, iRadimed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.43, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iRadimed's current EV-to-FCF of 43.69 is 78.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on iRadimed and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iRadimed's current EV-to-FCF is 43.69, which is near median its own 10-year median of 43.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRadimed stock overvalued right now?
Based on GuruFocus' analysis, iRadimed (IRMD) is currently considered Significantly Overvalued. The stock's GF Value™ is $65.94, compared to a current price of $87.87 — trading 33.3% above its estimated fair value. The current EV-to-FCF is 43.69, which is near median its 10-year median of 43.67 and 78.8% above the Medical Devices & Instruments industry median of 24.43. iRadimed's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For iRadimed (IRMD), the current EV-to-FCF is 43.69 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRadimed (IRMD) Overvalued in 2026?
Based on GuruFocus' analysis, iRadimed stock appears to be overvalued.
The current stock price of $87.87 is trading 33.3% above its estimated GF Value™ of $65.94.
GuruFocus considers iRadimed to be Significantly Overvalued.
Key valuation signals for IRMD:
EV-to-FCF: 43.69 (near median its 10-year median of 43.67)
GF Value™: $65.94 vs. price of $87.87 (33.3% above fair value)
Industry Position: 78.8% above the Medical Devices & Instruments median (#302 of 409)
No single metric tells the full story. See the IRMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
93GF Score
Get the complete analysis for IRMD
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRMD has been successfully added to your 
